Jie-Bing Tan

Safety and immunogenicity of inactivated human Rotavirus vaccine in young children and infants: a randomized, placebo-controlled, double-blind, phase I clinical trial

IRV was well tolerated, with no vaccine-related SAEs in any of the cohorts; the authors observed clinically manageable transient mild-to-moderate fever in the high dose infant group and the 3-dose schedule outperformed the 2-dose regimen.